StudyFinder

MT2015-25: Tandem Myeloablative Consolidation Therapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

Status: Recruiting

To evaluate 3 year progression free survival (PFS) rate of high-risk neuroblastoma patients after treatment with a tandem consolidation of Thiotepa/ Cyclophosphamide and PBSC rescue followed by Carboplatin/Etoposide/ Melphalan (CEM) and PBSC rescue, as compared to historical controls of a single CEM consolidation course with PBSC rescue.

I'm interested

Age: Not specified
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• less than 30 years old when diagnosis of neuroblastoma is made
• no uncontrolled infection
• recovered from acute toxicities of last cycle of induction chemotherapy
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Conditions:

Cancer

Keywords:

Neuroblastoma

Contact(s): Holly Franceen - hfrancee@umn.edu
Principal Investigator: Ashish Gupta
Phase: PHASE2
IRB Number: 1601M82901
System ID: 16776
See this study on ClinicalTrials.gov

Back